The factors contributing to the growth of remdesivir market include, rising number of coronavirus disease (COVID-19) and increasing government initiatives. The advantages of remdesivir observed during the trails such as shortened time of recovery by an average of four days is another key factor driving its demand. Agreements signed by Gilead with generic manufacturers to deliver treatment at a substantially lower cost in the developing countries is also anticipated to boost the market growth during the forecast period. However, the possibility of shortage of the drug and the concerns related to the safety and efficacy of remdesivir amongst the patient population are some factors that are likely to hinder the market growth to a certain extent.
Major Key Players of the Remdesivir Market are:
Gilead Sciences, Inc., BrightGene Bio-Medical Technology Co.,Ltd., Hainan Haiyao Co., Ltd., EVA PHARM, Cipla Inc., Mylan N.V., Hetero, Ferozsons Laboratories, Zydus Cadila, Dr. Reddy’s Laboratories Ltd. and Beximco Pharmaceuticals Ltd., among others.
The initial novel coronavirus outbreak in China led to COVID-19 pandemic. COVID-19 has rapidly affected millions of lives worldwide thereafter. For instance, in U.S by the end of June 2020 there were approximately 3.1 million total cases with active cases being around 1.5 million. Rapid surge in the number of COVID-19 cases is expected to drive the growth of remdesivir market. Moreover, results from the NIAID study on patients hospitalized with COVID-19 showcased that remdesivir shortened time to recovery by an average of four days. This positive result is expected to spur its demand in the coming years.
The Remdesivir Market is segmented on the basis of Form, Patient Type, Application and region.
Major Form of Remdesivir Market covered are:
- Lyophilized Powder
- Concentrated Solution
Major Patient Type of Remdesivir Market covered are:
- Pediatric Patient
- Adult Patients
Major End Users of Remdesivir Market covered are:
- Hospitals
- Clinics
No comments:
Post a Comment